A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age14-75
SponsorChinese PLA General Hospital
About this trial
The purpose of this study is to compare the efficacy and safety of venetoclax combined with the CACAG regimen with the traditional "3+7" regimen in the treatment of newly diagnosed intermediate- or high-risk acute myeloid leukemia (AML).
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
- "3+7"
Treatment groups
160 Participants
are divided into 2 treatment groupsSponsors and collaborators
Chinese PLA General Hospital
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Collaborator
Yantai Yuhuangding Hospital
Collaborator
The General Hospital of Western Theater Command
Collaborator
940 Hospital of the People's Liberation Army Joint Logistic Support Force
Collaborator
960th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Collaborator
Jining First People's Hospital
Collaborator
Source ClinicalTrials.gov